

[Chem. Pharm. Bull.]
31(7) 2349—2352 (1983)

Synthesis and Activity of a newly Isolated Analgesic Pentapeptide, Neo-kyotorphin¹⁾

KOUKI KITAGAWA,^{*,a} NOBUYUKI KAWAI,^a YOSHIKI KISO,^a TADASHI AKITA,^a
KIYOSHI FUKUI,^b HIROO AMANO,^c and HIROSHI TAKAGI^c

*Faculty of Pharmaceutical Sciences, University of Tokushima,^a Shomachi, Tokushima 770, Japan,
Department of Pharmacology, Kagawa Medical School,^b Miki-cho, Kida-gun,
Kagawa 761-07, Japan, and Faculty of Pharmaceutical Sciences,
Kyoto University,^c Sakyo-ku, Kyoto 606, Japan*

(Received December 8, 1982)

A newly isolated bovine brain pentapeptide, Thr-Ser-Lys-Tyr-Arg (neo-kyotorphin), which contains the Tyr-Arg (kyotorphin) unit at its carboxyl terminal portion, was synthesized by using the TFMSA-TFA-thioanisole deprotecting procedure. The synthetic peptide exhibited dose-dependent analgesic activity in mice at a level approximately equal to that of Leu-enkephalin.

Keywords—peptide synthesis; TFMSA-TFA-thioanisole deprotecting system; kyotorphin; neo-kyotorphin; analgesic activity

In 1979, Takagi *et al.* isolated and identified an analgesic dipeptide, kyotorphin (H-Tyr-Arg-OH), from the bovine brain.^{2,3)} During the course of isolation studies of kyotorphin, they found another novel peptide in the methanol-soluble fraction of the bovine brain, and quite recently they isolated and determined its structure as H-Thr-Ser-Lys-Tyr-Arg-OH.⁴⁾

This peptide contains the kyotorphin sequence at the carboxyl terminal portion and has analgesic activity, like kyotorphin. Thus, this peptide may be a precursor of kyotorphin. Moreover, it is interesting to note that this sequence corresponds to the carboxyl terminal pentapeptide of the α -chain of human (bovine) hemoglobin,^{5,6)} while the amino terminal tripeptide, Thr-Ser-Lys-NH₂, has already been isolated from the bovine pineal glands as an antigonadotropic peptide.⁷⁾ However, the relation between this pentapeptide and hemoglobin is not clear.

In this paper, we report the synthesis of this newly isolated pentapeptide, neo-kyotorphin.

The synthetic scheme is outlined in Fig. 1.

First, the protected tripeptide was prepared by the azide condensation of Z(OMe)-Lys(Z)-Tyr-NHNH₂ and H-Arg(Tos)-OH. Alternatively, we tried to prepare this tripeptide using the kyotorphin unit, namely by the condensation of Z(OMe)-Lys(Z)-OH and H-Tyr(2,6-Cl₂Bzl)-Arg(Tos)-OH⁸⁾ by HONB active ester method,⁹⁾ but the purification of this tripeptide was very troublesome because of contamination by Z(OMe)-Lys(Z)-OH.

After removal of the Z(OMe) group by TFA, Z(OMe)-Thr-Ser-NHNH₂¹⁰⁾ was condensed by the azide method to afford the protected pentapeptide, Z(OMe)-Thr-Ser-Lys(Z)-Tyr-Arg(Tos)-OH. This peptide was purified by silica gel column chromatography using CHCl₃-MeOH (9:1) and CHCl₃-MeOH-H₂O (8:3:1) as eluants. Final deprotection of this peptide was performed with the TFMSA-thioanisole in TFA system¹¹⁾ in the presence of *o*-cresol to suppress *O*-tosylation at the Tyr residue.¹²⁾ This deprotecting system completely removed the tosyl group of Arg within 2 h at room temperature, as reported previously.⁸⁾ The deprotected peptide was converted to the corresponding acetate and purified by column chromatography on Sephadex G-10 and CM-cellulose. In the former case, 3% acetic acid was




Fig. 1. Synthetic Scheme of Neo-kyotorphin

employed as the eluant and in the latter, gradient elution with 1 M ammonium acetate (pH 6.9) through a mixing flask (400 ml of H_2O) was carried out. Final desalting on Sephadex G-10 and repeated lyophilization gave the homogeneous peptide as a fluffy powder. The homogeneity of the synthetic peptide was assessed by thin layer chromatography (TLC) on a cellulose plate, amino acid analysis of an acid hydrolysate and enzymatic digest, elemental analysis and high performance liquid chromatography (HPLC).

This synthetic peptide was identical to the natural one on high performance thin layer chromatography (HPTLC) ($R_f=0.43$) and high voltage paper electrophoresis ($R_m=0.91$). These results confirm that the structure of neo-kyotorphin is $\text{H-Thr-Ser-Lys-Tyr-Arg-OH}$.

Synthetic neo-kyotorphin exhibited a dose-dependent analgesic effect after intracisternal injection in mice. The ED_{50} value (determined by the tail-pinch method) was 195 nmol/mouse. The analgesic activity of neo-kyotorphin is 5.6 times lower than that of kyotorphin ($\text{ED}_{50}=34.7$ nmol/mouse), and approximately equal to that of Leu-enkephalin ($\text{ED}_{50}=233$ nmol/mouse).

In the ileal contracting assay using isolated guinea-pig ileum, synthetic neo-kyotorphin had no contracting effect even at a dose of 2×10^{-7} M, and it showed no inhibitory effect on the electrically evoked contraction of isolated guinea-pig ileum at a dose of 1.3×10^{-4} M.

In preliminary experiments, it was found that the peptide bond between Lys^3 and Tyr^4 in neo-kyotorphin could be cleaved by a trypsin-like peptidase present in the brain, releasing Tyr-Arg (kyotorphin). Details of the analgesic activity of neo-kyotorphin will be reported elsewhere.

Experimental

The melting points are uncorrected. Rotations were determined with a Union PM-201 polarimeter. Acid hydrolyses were carried out in 6N HCl in the presence of a small amount of phenol. LAP (Lot. 79C-8110) was purchased from Sigma Chemical Co. Amino acid analyses were performed on a Hitachi 835 amino acid analyzer. Thin layer chromatography was carried out on silica gel (pre-coated Silica gel 60 F_{254} , Merck) or cellulose (pre-coated cellulose F, Merck). Solvent systems used were $R_{f1}=\text{CHCl}_3\text{-MeOH-H}_2\text{O}$ (8:3:1), $R_{f2}=n\text{-BuOH-pyridine-AcOH-H}_2\text{O}$ (30:20:6:24).

Z(OMe)-Lys(Z)-Tyr-OEt—DCC (4.12 g) was added to a solution of Z(OMe)-Lys(Z)-OH (8.90 g) and H-Tyr-OEt (prepared from 4.91 g of the hydrochloride with 2.8 ml of Et₃N) in DMF (80 ml) and the solution was stirred for 48 h at room temperature. The urea derivative was removed by filtration, then the filtrate was concentrated and the residue was dissolved in AcOEt. The solution was washed with 5% Na₂CO₃, 10% citric acid and water successively, dried over Na₂SO₄, and concentrated. The addition of petroleum ether to the oily residue gave a solid product, which was recrystallized from AcOEt-ether. Yield 10.1 g (80.0%), mp 86–88 °C, $[\alpha]_D^{25} -6.4^\circ$ ($c=2.5$, MeOH), R_f 0.70. *Anal.* Calcd for C₃₄H₄₁N₃O₉: C, 64.24; H, 6.50; N, 6.61. Found: C, 64.19; H, 6.70; N, 6.53.

Z(OMe)-Lys(Z)-Tyr-NHNH₂—Z(OMe)-Lys(Z)-Tyr-OEt (9.53 g) was dissolved in a mixture of MeOH (50 ml) and DMF (50 ml), then treated with hydrazine hydrate (7.5 ml) at room temperature overnight. The reaction mixture was diluted with MeOH and the precipitated product was collected by filtration and washed with MeOH. Yield 8.0 g (84.0%), mp 220–222 °C, $[\alpha]_D^{25} -12.0^\circ$ ($c=2.5$, DMF), R_f 0.68. *Anal.* Calcd for C₃₂H₃₉N₅O₈: C, 61.82; H, 6.32; N, 11.27. Found: C, 61.90; H, 6.33; N, 11.02.

Z(OMe)-Lys(Z)-Tyr-Arg(Tos)-OH—The azide (prepared from 3.10 g of Z(OMe)-Lys(Z)-Tyr-NHNH₂ with 5.62 ml of 2.7 N HCl-dioxane, 0.67 ml of isoamyl nitrite and 2.1 ml of Et₃N) in DMF (30 ml) was added to a solution of N-Arg (Tos)-OH (3.28 g) in DMF (20 ml) containing Et₃N (1.4 ml). After being stirred for 48 h at 4 °C, the mixture was concentrated and the residue was dissolved in a mixture of AcOEt and 10% citric acid. The organic phase was washed with 10% citric acid, saturated NaCl and water, dried over Na₂SO₄, and concentrated. Addition of ether to the oily residue gave a solid product, which was recrystallized from AcOEt. Yield 4.10 g (89.0%), mp 115–118 °C, $[\alpha]_D^{25} -10.0^\circ$ ($c=2.5$, MeOH), R_f 0.39. *Anal.* Calcd for C₄₅H₅₅N₇O₁₂S·H₂O: C, 57.74; H, 6.14; N, 10.48. Found: C, 57.71; H, 6.07; N, 10.05.

Z(OMe)-Thr-Ser-Lys(Z)-Tyr-Arg(Tos)-OH—Z(OMe)-Lys(Z)-Tyr-Arg(Tos)-OH (3.21 g) was treated with TFA (10 ml) in the presence of anisole (2.0 ml) for 45 min at room temperature. Excess TFA was evaporated off *in vacuo* at 35 °C, then ether was added. The precipitated TFA salt was collected by filtration, dried over KOH pellets for 2 h, then dissolved in DMF (20 ml) containing Et₃N (0.5 ml). To this ice-chilled solution was added the azide (prepared from 2.69 g of Z(OMe)-Thr-Ser-NHNH₂ with 8.08 ml of 2.7 N HCl-dioxane, 0.93 ml of isoamyl nitrite and 2.94 ml of Et₃N) in DMF (30 ml). After being stirred for 48 h at 4 °C, the mixture was concentrated and the oily residue was dissolved in a mixture of AcOEt and 10% citric acid. The organic phase was washed with 10% citric acid, saturated NaCl and water successively, dried over Na₂SO₄, and concentrated. Addition of ether to the residue gave a solid product. For further purification, this product was dissolved in a small amount of CHCl₃-MeOH (9:1, v/v) and applied to a column of silica (3.3 × 25 cm), which was eluted with the same solvent, followed by CHCl₃-MeOH-H₂O (8:3:1, v/v). The fractions containing the substance of R_f 0.22 were combined and the solvent was evaporated off. The residue was triturated with ether and the resulting powder was recrystallized from MeOH-AcOEt. Yield 2.95 g (76.0%), mp 116–119 °C, $[\alpha]_D^{25} -12.4^\circ$ ($c=2.5$, MeOH), R_f 0.22. *Anal.* Calcd for C₅₂H₆₇N₉O₁₆S·H₂O: C, 54.68; H, 6.27; N, 11.04. Found: C, 54.90; H, 6.45; N, 10.91. Amino acid analysis of an acid hydrolysate gave the following ratios: Thr 0.93 Ser 0.89 Lys 1.02 Tyr 1.00 Arg 0.89 (average recovery, 91%).

H-Thr-Ser-Lys-Tyr-Arg-OH (Neo-kyotorphin)—The above protected pentapeptide (630 mg; 0.5 mm) was treated with TFA (12 ml) in the presence of thioanisole (3.1 ml; 50 eq.) and *o*-cresol (2.7 ml; 50 eq.) in ice-bath for 30 min, then TFMSA (1.2 ml) was added. The reaction mixture was stirred for 3 h at room temperature, and TFA was evaporated off *in vacuo* at 30 °C. After being washed with *n*-hexane, the oily residue was dried over KOH pellets for 1 h, then dissolved in H₂O (50 ml) and treated with Amberlite IR-400 (acetate form, approximately 5 g) for 30 min. The resin was removed by filtration and washed with a small amount of 10% AcOH (10 ml). This solution was washed with ether, then the pH was adjusted to 10 with 5% NH₄OH and after 30 min, to 7 with 3% AcOH. The solution was lyophilized and the residue was dissolved in 3% AcOH (3 ml). The solution was applied to a column of Sephadex G-10 (2.6 × 100 cm), which was eluted with 3% AcOH and the absorbancy of each fraction (5 ml) was determined at 275 nm. The first main fractions (tube no. 51–73) were combined and the solvent was removed by lyophilization to give a crude product (155 mg; 41%).

The crude product (95 mg) was dissolved in H₂O (100 ml) and applied to a column of CM-cellulose (2.8 × 28 cm), which was eluted with H₂O (100 ml) and a linear gradient of 1 M AcONH₄ (pH 6.9) through a mixing flask (400 ml of H₂O). Individual fractions (10 ml each) were collected and the absorbancy at 275 nm was determined. After a small peak (tube no. 44–47), the main peak (tube no. 48–55) was combined and the solvent was removed by repeated lyophilization. For the final desalting, the lyophilized material was dissolved in 3% AcOH (5 ml) and passed through a column of Sephadex G-10 (2.6 × 100 cm). A white fluffy powder was recovered from a single chromatographic peak fraction after repeated lyophilization (82 mg; 87% recovery). $[\alpha]_D^{25} -21.7^\circ$ ($c=1.2$, 3% AcOH), R_f 0.43 (cellulose plate). *Anal.* Calcd for C₂₈H₄₇N₉O₉·2CH₃COOH·3H₂O: C, 46.42; H, 7.43; N, 15.23. Found: C, 46.29; H, 7.18; N, 14.79. Amino acid analysis of an acid hydrolysate gave the following ratios: Thr 0.91 Ser 0.86 Lys 1.00 Tyr 0.98 Arg 0.83 (average recovery; 91%). Amino acid analysis after LAP digestion gave the following ratios: Thr 1.00 Ser 1.00 Lys 1.00 Tyr 0.98 Arg 1.02 (average recovery; 94%). Reverse-phase HPLC was carried out with a Waters compact model, using a μ Bondapak C₁₈ (0.39 × 30 cm) column and a solvent system of 0.1 M KH₂PO₄ containing 2% acetonitrile at a flow rate of 1 ml/min. The synthetic peptide exhibited a single peak at a retention time of 6.70 min under the above conditions.

Bioassay—a) Analgesic Activity: The analgesic effect of the synthetic peptide was examined by using the intracisternal injection technique in mice, according to the method reported previously.¹³⁾

b) Ileal Contracting Activity: Ileal contracting activity was determined by using isolated guinea-pig ileum by the method reported by Segawa *et al.*,¹⁴⁾ and the inhibitory effect on the electrically evoked contraction of the isolated guinea-pig ileum was determined by the method reported by Kosterlitz *et al.*¹⁵⁾

Acknowledgements We wish to express our gratitude to Professors Haruaki Yajima and Kyoza Hayashi for their encouragement during the course of this investigation. Thanks are also extended to Dr. Nobutaka Fujii for amino acid analysis of an enzymatic hydrolysate and to Dr. Hideki Moritoki for helpful discussions.

References and Notes

- 1) Amino acids, peptides and their derivatives in this paper are of the L-configuration. Abbreviations used are those recommended by the I.U.P.A.C.-I.U.B. Commission on Biochemical Nomenclature: *J. Biol. Chem.*, **247**, 977 (1972). Z = benzyloxycarbonyl, Z(OMe) = *p*-methoxybenzyloxycarbonyl, 2,6-Cl₂Bzl = 2,6-dichlorobenzyl, Tos = *p*-toluenesulfonyl, TFA = trifluoroacetic acid, TFMSA = trifluoromethanesulfonic acid, HONB = *N*-hydroxy-5-norbornene-2,3-dicarboximide, DCC = *N,N'*-dicyclohexylcarbodiimide, Et₃N = triethylamine, DMF = dimethylformamide.
- 2) H. Takagi, H. Shiomi, H. Ueda, and H. Amano, *Nature* (London), **282**, 410 (1979).
- 3) H. Shiomi, H. Ueda, and H. Takagi, *Neuropharmacol.*, **20**, 633 (1981).
- 4) H. Takagi, H. Shiomi, K. Fukui, K. Hayashi, Y. Kiso, and K. Kitagawa, *Life Sci.*, **31**, 1733 (1982).
- 5) R. J. Hill and W. Konigsberg, *J. Biol. Chem.*, **238**, 3151 (1962).
- 6) W. A. Schroeder, J. R. Shelton, J. B. Shelton, B. Robberson, and D. R. Babin, *Arch. Biochem. Biophys.*, **120**, 1 (1967).
- 7) R. J. Orts, T. Liao, J. L. Sartin, and B. Bruot, *The Physiologist*, **21**, 87 (1978).
- 8) Y. Kiso, M. Satomi, K. Ukawa, and T. Akita, *J. Chem. Soc., Chem. Commun.*, **1980**, 1063.
- 9) M. Fujino, S. Kobayashi, M. Obayashi, T. Fukuda, and O. Nishimura, *Chem. Pharm. Bull.*, **22**, 1857 (1974).
- 10) H. Ogawa, M. Sugiura, H. Yajima, H. Sakurai, and K. Tsuda, *Chem. Pharm. Bull.*, **26**, 1549 (1978).
- 11) Y. Kiso, K. Ukawa, S. Nakamura, K. Ito, and T. Akita, *Chem. Pharm. Bull.*, **28**, 673 (1980).
- 12) H. Yajima, M. Takeyama, J. Kanaki, and K. Mitani, *J. Chem. Soc., Chem. Commun.*, **1978**, 482; H. Yajima, M. Takeyama, J. Kanaki, O. Nishimura, and M. Fujino, *Chem. Pharm. Bull.*, **26**, 3752 (1978).
- 13) H. Ueda, H. Amano, H. Shiomi, and H. Takagi, *Eur. J. Pharmacol.*, **56**, 265 (1979).
- 14) T. Segawa, K. Hosokawa, K. Kitagawa, and H. Yajima, *J. Pharm. Pharmacol.*, **29**, 57 (1977).
- 15) H. W. Kosterlitz and A. J. Watt, *Br. J. Pharmacol. Chemother.*, **33**, 266 (1968).